CNBC's Meg Tirrell discusses the latest healthcare mergers and acquisitions.
Pfizer buys Medivation for $14 billion in cash. CNBC's Meg Tirrell reports the latest.
Shares of Mylan are under pressure as word spreads about the increased price of its EpiPen drug by 500 percent. David Maris, Wells Fargo managing director, shares his take.
The FDA approves two transcatheter heart valves manufactured by Edwards Lifesciences, CNBC's Seema Mody reports.
CNBC's Seema Mody reports the latest on Monsanto, including the company only giving Bayer selective access to confidential information.
CNBC's Brian Sullivan discusses three stocks he deems most interesting.
Earnings are out for Nvidia and Planet Fitness. CNBC's Susan Li reports the details for both companies.
Peder Holk Nielsen, Novozymes CEO, explains why economic uncertainty has caused the company to lower its earning guidance.
CNBC's Kate Kelly reports the latest details on Bill Ackman's Valeant stake.
Shares of Valeant surge as the company affirms forward guidance. CNBC's Meg Tirrell reports the details, including what CEO Joseph C. Papa has to say.
Shares of Bristol-Myers Squibb briefly fell more than 17 percent in opening trade Friday after its cancer drug failed to meet targets in a late-stage study.
Shares of Bristol Myers Squibb are way down today while shares of Merck are up. Here's why, and what's next, with Tony Butler, Guggenheim Securities.
While Bristol Myers Squibb is having its worst day in nearly 16 years, shares of Merck is up 5 percent year over year. Nancy Tengler, Heartland Financial, discusses one of her largest holdings.
Bristol Myers Squibb is having its worst day in nearly 16 years after failing to meet goals for a lung cancer drug. Alex Arfaei, BMO, discusses.
CNBC's Meg Tirrell reports why Bristol-Myers shares are dropping while Merck shares are soaring. The “Fast Money Halftime Report” traders; Stephanie Link, TIAA Global Asset Management; and John Spallanzani, GFI Group chief macro strategist, discuss their views on buying Bristol-Myers on the dip.
Biotech stocks have seen a big bounce in the past few weeks, as the group hits its highest level since January. Talking biotech, with David Seaburg, Cowen, and Chad Morganlander, Stifel Nicolaus.
CNBC's Josh Lipton reports the latest on nootropics, a biohacking trend tech workers are turning to for peak mental and physical performance.
The $75 billion Biogen may be vulnerable to a takeover, but it makes a risky target at a likely value approaching $90 billion.
Biotech hits a 6-month high. The "Fast Money Halftime Report" traders discusses whether they think it's time to buy biotech.
The "Fast Money" traders said on Tuesday that mergers and acquisitions may help the biotechnology sector hit new highs.